Get the Stockscreener App
3.30
1.85%
0.06
After Hours:
3.30
Cytek Biosciences Inc stock is traded at $3.30, with a volume of 771.51K.
It is up +1.85% in the last 24 hours and up +3.45% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$3.24
Open:
$3.26
24h Volume:
771.51K
Relative Volume:
0.68
Market Cap:
$417.98M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-36.67
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
-7.30%
1M Performance:
+3.45%
6M Performance:
-39.56%
1Y Performance:
-50.67%
1-Day Range:
$3.25
$3.375
1-Week Range:
$3.205
$3.55
52-Week Range:
$2.37
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
3.30 | 453.44M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
120.51 | 231.78B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.65 | 152.32B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.90 | 149.83B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.53 | 114.03B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.18 | 45.28B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
How Cytek Biosciences Inc. stock performs during market volatilityDaily Swing Candidates - Newser
What makes Cytek Biosciences Inc. stock price move sharplyFree Expert-Led Investment Training - Newser
Why Cytek Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Swing Trading Strategies - Newser
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by New York State Teachers Retirement System - Defense World
Wealth Enhancement Advisory Services LLC Invests $63,000 in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
MDxHealth names Michael Holder to board, CFO Ron Kalfus to depart - Investing.com
Research device company to relocate local office to Bellevue - The Business Journals
Cytek Biosciences (NASDAQ:CTKB) Trading Up 2.4% – Still a Buy? - Defense World
3 Promising Penny Stocks With Market Caps At Least $300M - Yahoo Finance
Cytek Biosciences Elects New Directors at Annual Meeting - TipRanks
Cytek Biosciences shareholders elect directors and approve auditor at annual meeting - Investing.com
Ratios Revealed: Decoding Cytek BioSciences Inc (CTKB)’s Financial Health - DWinneX
Flow Cytometer | Cytek Biosciences Inc. | Products - Photonics Spectra
Cytek Biosciences at Goldman Sachs Conference: Growth Amidst Challenges By Investing.com - Investing.com Canada
Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Cytek Biosciences (CTKB) Faced Challenges from NIH Funding Reductions - Insider Monkey
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,433 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences Plunges 10.18% Amid Product Discontinuation Concerns - AInvest
Insider Buying: William Mccombe Acquires 35,000 Shares of Cytek Biosciences Inc (CTKB) - GuruFocus
Bank of America Corp DE Boosts Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences Leads Our Top 3 Penny Stock Selections - Yahoo Finance
ProShare Advisors LLC Has $235,000 Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Jane Street Group LLC - Defense World
Ameriprise Financial Inc. Has $1.62 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System - MSN
Optimizing Lab Efficiency with Cytek's Aurora Evo Flow Cytometer - Lab Manager
The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31% - simplywall.st
Cytek announces new full spectrum flow cytometer - SelectScience
Where are the Opportunities in (CTKB) - news.stocktradersdaily.com
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - SINA HONG KONG LIMITED
Cytek® Biosciences Is Setting the New Standard for Full - GlobeNewswire
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - GlobeNewswire Inc.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Millennium Management LLC - Defense World
Deutsche Bank AG Acquires 36,542 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Given New $7.00 Price Target at Morgan Stanley - Defense World
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Cytek Management Sets Key Investor Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock - Benzinga
Cytek Biosciences (CTKB) Price Target Reduced by Morgan Stanley - GuruFocus
Cytek Biosciences (CTKB) Price Target Reduced by Morgan Stanley | CTKB Stock News - GuruFocus
Cytek Biosciences (CTKB) Price Target Revised by Morgan Stanley - GuruFocus
Cytek Biosciences (CTKB) Price Target Revised by Morgan Stanley | CTKB Stock News - GuruFocus
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 10% drop adds to a year losses - simplywall.st
Cytek Biosciences Introduces a New High-Dimensional Sorter - Lab Manager
Cytek Biosciences stock hits 52-week low at $2.5 amid market challenges - Investing.com Canada
BNP Paribas Financial Markets Takes Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):